<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944045</url>
  </required_header>
  <id_info>
    <org_study_id>P150961</org_study_id>
    <secondary_id>2016-002275-10</secondary_id>
    <nct_id>NCT02944045</nct_id>
  </id_info>
  <brief_title>Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients</brief_title>
  <acronym>PIC</acronym>
  <official_title>Intérêt de la corticothérapie Dans la Pneumocystose Grave du Patient immunodéprimé Non VIH. Essai Prospectif Multicentrique Randomisé Contrôlé : PIC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pneumocystis jiroveci pneumonia (PcP) increased in non HIV immunocompromised patients.
      Mortality remains high for those patients with comorbidities (50% for patients with the most
      severe Pneumocystis pneumonia). Physiopathology, characteristics and outcome of PcP in
      non-HIV patients remains different from those in HIV patients. Steroids in HIV patients with
      PcP has been associated with decreased mortality but in non-HIV patients, adjunctive steroids
      remains controversy. Some retrospective studies in that field did not find any beneficial
      effects of steroids ((1mg/kg/jour d'Equivalent Prednisone (EP)). However, all the studies
      were retrospective, non randomised studies including various underlying disease and severity
      of PcP was variable. Moreover, dosage and delay of steroids were variable leading difficult
      to interpret all the results.

      The investigators want to demonstrate the beneficial effect of steroid during PcP in non-HiV
      immunocompromised patients with a double blinded randomised clinical trials comparing
      adjunctive steroids to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>28 days mortality after the randomisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 90</time_frame>
    <description>90 days mortality after the randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>Day 120</time_frame>
    <description>Mortality at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Day 90</time_frame>
    <description>For patients admitted to ICU at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute respiratory failure</measure>
    <time_frame>Day 28</time_frame>
    <description>Acute respiratory failure during treatment defined by one of those criteria within 28 days :
Increased need of oxygen (more than 9 l/min of high flow nasal oxygen with Inspired Fraction of Oxygen (fiO2) &gt;50%)
Admission to ICU after randomisation
Need of mechanical ventilation (invasive or non invasive) or high flow nasal oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Duration of mechanical ventilation invasive and/or non invasive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of septic shock</measure>
    <time_frame>Day 28</time_frame>
    <description>septic shock is defined as need for vasopressor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute kidney injury</measure>
    <time_frame>Day 28</time_frame>
    <description>KDIGO score &gt;=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital acquired infectious disease</measure>
    <time_frame>Day 28</time_frame>
    <description>Global incidence incidence of infections. Incidence of pulmonary or extra-pulmonary infections.
Incidence of bacterial, viral and fungal infections. Diagnosis of infectious disease will be defined by the need of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Day 120</time_frame>
    <description>Hospital length of stay at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Day 90</time_frame>
    <description>ICU length of stay at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Insulin treatment</measure>
    <time_frame>Day 28</time_frame>
    <description>Insulin treatment is defined :
patient without insulin treatment before study : start of insulin therapy
patient treated with insulin before study : increased dose (&gt;30%) of insulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Pneumocystis</condition>
  <condition>Steroids</condition>
  <condition>Immunocompromised Patient</condition>
  <condition>Hematologic Neoplasms</condition>
  <condition>Immunosuppressive Agents</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline serum, same volume as in the Experimental arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednisolone intra veinous
Day 1 to 5 : 30mg twice per day
Day 6 to 10 : 30mg per day
Day 11 to 21 : 20mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone intra veinous
Day 1 to 5 : 30mg twice per day
Day 6 to 10 : 30mg per day
Day 11 to 21 : 20mg per day</description>
    <arm_group_label>Steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>saline serum</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Severe PcP : 1 / interstitial acute pneumonia with possible or typical criteria for
             PcP and positive specimen for Pneumocystis jirovecii (excluding PCR) ; or interstitial
             acute pneumonia with typical criteria for PcP and positive PCR in respiratory
             specimen. 2/ Arterial pression of Oxygen (PaO2) &lt; 60 mmHg on room air need of 3 L/min
             oxygen for saturation &gt;92% or tachypnea&gt;30min need of mechanical ventilation for acute
             respiratory failure.

          -  Treatment for PcP started for less than 7 days.

          -  Non-HIV immunosuppression : malignant hematological disease, solid tumor cured for
             less than 5 years, allogenic stem cell transplant, Steroids (&gt;0.3mg/kg equivalent
             prednisone for more than 3 weeks or &gt; 20mg/days for more than one months) or other
             immunosuppressive treatment for more than one months or solid organ transplantation.

          -  Signed inform consent by patient or relatives

          -  Health insurance

        Exclusion Criteria:

          -  HIV Serology HIV 1 or 2 positive

          -  Need of steroid ≥1mg/kg/j equivalent prednisone for another pathology (acute Graft
             versus Host disease (GVH= for example)

          -  Contra-indication for steroids

          -  Pregnancy of breath-feeding

          -  Denied to participate

          -  No health insurance

          -  tutelage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginie Lemiale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elie Azoulay, MD PHD</last_name>
    <role>Study Director</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virginie Lemiale, MD</last_name>
    <phone>142499419</phone>
    <phone_ext>+33</phone_ext>
    <email>virginie.lemiale@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu Resche-Rigon, MD PHD</last_name>
    <phone>142499742</phone>
    <phone_ext>+33</phone_ext>
    <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical ICU</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>virginie lemiale, MD</last_name>
      <phone>142499419</phone>
      <phone_ext>+33</phone_ext>
      <email>virginie.lemiale@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Pneumocystis Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

